Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa. The Big Biotech is turning to TV again to promote its hep C franchise, this ...

More than a decade before Gilead’s patents expire for blockbuster hep C drugs Epclusa and Harvoni, the company is actually launching authorized generics at one-third the list price—or less. To say ...

Gilead Sciences said Monday it will launch generic versions of Harvoni and Epclusa, its top-selling hepatitis C drugs. Gilead will sell its chronic hepatitis C generics at a $24,000 list price for the ...

More than a decade ahead of their patents’ expiration dates, Gilead Sciences is releasing authorized generics of two of its hepatitis C drugs. The launch is planned to happen more than a decade ahead ...

BARCELONA, Spain — What started with a single patient with hepatitis C insisting that he would take generic direct-acting antiviral medication imported from China with or without the help of his ...